These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6224711)

  • 1. Obesity, serum steroid levels, and pulsatile gonadotropin secretion in polycystic ovarian disease.
    Laatikainen T; Tulenheimo A; Andersson B; Kärkkäinen J
    Eur J Obstet Gynecol Reprod Biol; 1983 Apr; 15(1):45-53. PubMed ID: 6224711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.
    Waldstreicher J; Santoro NF; Hall JE; Filicori M; Crowley WF
    J Clin Endocrinol Metab; 1988 Jan; 66(1):165-72. PubMed ID: 2961784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
    Holte J; Bergh T; Gennarelli G; Wide L
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine dynamics during pulsatile GnRH administration in patients with hypothalamic amenorrhea and polycystic ovarian disease.
    Rossmanith WG; Wirth U; Benz R; Wolf AS
    Gynecol Endocrinol; 1989; 3(1):21-34. PubMed ID: 2658471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.
    Anttila L; Koskinen P; Kaihola HL; Erkkola R; Irjala K; Ruutiainen K
    Fertil Steril; 1992 Oct; 58(4):697-702. PubMed ID: 1426312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
    Nestler JE; Powers LP; Matt DW; Steingold KA; Plymate SR; Rittmaster RS; Clore JN; Blackard WG
    J Clin Endocrinol Metab; 1991 Jan; 72(1):83-9. PubMed ID: 1898744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
    Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
    Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hormonal response of patients with polycystic ovarian disease to subcutaneous low frequency pulsatile administration of luteinizing hormone-releasing hormone.
    Hurwitz A; Rosenn B; Palti Z; Ebstein B; Har-Nir R; Ron M
    Fertil Steril; 1986 Sep; 46(3):378-84. PubMed ID: 2943606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of obesity on hormonal parameters in hirsute and nonhirsute women.
    Bernasconi D; Del Monte P; Meozzi M; Randazzo M; Marugo A; Badaracco B; Marugo M
    Metabolism; 1996 Jan; 45(1):72-5. PubMed ID: 8544780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease.
    Anttila L; Ding YQ; Ruutiainen K; Erkkola R; Irjala K; Huhtaniemi I
    Fertil Steril; 1991 Jun; 55(6):1057-61. PubMed ID: 1903726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
    Arroyo A; Laughlin GA; Morales AJ; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
    Judd HL; Rigg LA; Anderson DC; Yen SS
    J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex steroids, adiposity and smoking in the pathogenesis of idiopathic hirsutism and polycystic ovary syndrome.
    Byrne B; Cunningham S; Igoe D; Conroy R; McKenna TJ
    Acta Endocrinol (Copenh); 1991 Apr; 124(4):370-4. PubMed ID: 1827700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.